Protumor activities of the immune response: Insights in the mechanisms of immunological shift, oncotraining, and oncopromotion

Journal of Oncology

Volumn , Issue , 2013, Pages

  Chimal Ramirez G K ^a,b   Espinoza Sanchez N A ^a,c   Fuentes Panana E M ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^c UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; COLONY STIMULATING FACTOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 6; METALLOPROTEINASE; PROSTAGLANDIN E2; PROTEINASE; REACTIVE OXYGEN METABOLITE; STROMAL CELL DERIVED FACTOR 1; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ADAPTIVE IMMUNITY; ANGIOGENESIS; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; BLOOD VESSEL PERMEABILITY; CANCER PROGNOSIS; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ENZYME RELEASE; EPITHELIAL MESENCHYMAL TRANSITION; HELICOBACTER INFECTION; HUMAN; IMMUNOLOGICAL SHIFT; IMMUNOSURVEILLANCE; INFLAMMATION; INNATE IMMUNITY; MACROPHAGE; MAST CELL; METASTASIS; NEUTROPHIL; NONHUMAN; ONCOPROMOTION; ONCOTRAINING; REGULATORY T LYMPHOCYTE; REVIEW; SOMATIC CELL; SUPPRESSOR CELL; TH1 CELL; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

EID: 84876527124     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2013/835956     Document Type: Review

References (174)

1. Burnet F. M., The concept of immunological surveillance. Progress in Experimental Tumor Research 1970 13 1 27 2-s2.0-0014887939
2. Thomas L., On immunosurveillance in human cancer. The Yale Journal of Biology and Medicine 1982 55 3-4 329 333 2-s2.0-0020262511 (Pubitemid 13119667)
3. Balkwill F. R., Mantovani A., Cancer-related inflammation: common themes and therapeutic opportunities. Seminars in Cancer Biology 2012 22 1 33 40 10.1016/j.semcancer.2011.12.005
4. DeNardo D. G., Andreu P., Coussens L. M., Interactions between lymphocytes and myeloid cells regulate pro-versus anti-tumor immunity. Cancer and Metastasis Reviews 2010 29 2 309 316 2-s2.0-77954563614 10.1007/s10555-010- 9223-6
5. Shankaran V., Ikeda H., Bruce A. T., White J. M., Swanson P. E., Old L. J., Schreiber R. D., IFN γ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001 410 6832 1107 1111 2-s2.0-0035953308 10.1038/35074122 (Pubitemid 32391043)
6. Ribatti D., Crivellato E., Mast cells, angiogenesis and cancer. Advances in Experimental Medicine and Biology 2011 716 270 288 2-s2.0-79960896329 10.1007/978-1-4419-9533-9-14
7. Kokenyesi R., Ovarian carcinoma cells synthesize both chondroitin sulfate and heparan sulfate cell surface proteoglycans that mediate cell adhesion to interstitial matrix. Journal of Cellular Biochemistry 2001 83 2 259 270 2-s2.0-0034833281 10.1002/jcb.1230 (Pubitemid 32896596)
8. Oldford S. A., Haidl I. D., Howatt M. A., Leiva C. A., Johnston B., Marshall J. S., A critical role for mast cells and mast cell-derived IL-6 in TLR2-mediated inhibition of tumor growth. Journal of Immunology 2010 185 11 7067 7076 2-s2.0-78650663589 10.4049/jimmunol.1001137
9. Ch'ng S., Wallis R. A., Yuan L., Davis P. F., Tan S. T., Mast cells and cutaneous malignancies. Modern Pathology 2006 19 1 149 159 2-s2.0-32844470274 10.1038/modpathol.3800474 (Pubitemid 43250990)
10. Maltby S., Khazaie K., McNagny K. M., Mast cells in tumor growth: angiogenesis, tissue remodelling and immune-modulation. Biochimica et Biophysica Acta 2009 1796 1 19 26 2-s2.0-69049117556 10.1016/j.bbcan.2009.02.001
11. Della Rovere F., Granata A., Monaco M., Basile G., Phagocytosis of cancer cells by mast cells in breast cancer. Anticancer Research 2009 29 8 3157 3161 2-s2.0-68549122651
12. Pham C. T. N., Neutrophil serine proteases: specific regulators of inflammation. Nature Reviews Immunology 2006 6 7 541 550 2-s2.0-33745559712 10.1038/nri1841 (Pubitemid 43980526)
13. Scapini P., Lapinet-Vera J. A., Gasperini S., Calzetti F., Bazzoni F., Cassatella M. A., The neutrophil as a cellular source of chemokines. Immunological Reviews 2000 177 195 203 2-s2.0-0033647240
14. Colombo M. P., Lombardi L., Stoppacciaro A., Melani C., Parenza M., Bottazzi B., Parmiani G., Granulocyte colony-stimulating factor (G-CSF) gene transduction in murine adenocarcinoma drives neutrophil-mediated tumor inhibition in vivo: neutrophils discriminate between G-CSF-producing and G-CSF-nonproducing tumor cells. Journal of Immunology 1992 149 1 113 119 2-s2.0-0026681457
15. Di Carlo E., Forni G., Lollini P., Colombo M. P., Modesti A., Musiani P., The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood 2001 97 2 339 345 2-s2.0-0035863830 10.1182/blood.V97.2.339 (Pubitemid 32060315)
16. Welch D. R., Schissel D. J., Howrey R. P., Aeed P. A., Tumor-elicited polymorphonuclear cells, in contrast to 'normal' circulating polymorphonuclear cells, stimulate invasive and metastatic potentials of rat mammary adenocarcinoma cells. Proceedings of the National Academy of Sciences of the United States of America 1989 86 15 5859 5863 2-s2.0-0343381078 (Pubitemid 19217548)
17. Fridlender Z. G., Sun J., Kim S., Kapoor V., Cheng G., Ling L., Worthen G. S., Albelda S. M., Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell 2009 16 183 194
18. Gregory A. D., Houghton A. M., Tumor-associated neutrophils: new targets for cancer therapy. Cancer Research 2011 71 7 2411 2416 2-s2.0-79953328298 10.1158/0008-5472.CAN-10-2583
19. Rittmeyer D., Lorentz A., Relationship between allergy and cancer: an overview. International Archives of Allergy and Immunology 2012 159 216 225 10.1159/000338994
20. Turner M. C., Epidemiology: allergy history, IgE, and cancer. Cancer Immunology, Immunotherapy 2011 61 9 1493 1510 10.1007/s00262-011-1180-6
21. Geissmann F., Manz M. G., Jung S., Sieweke M. H., Merad M., Ley K., Development of monocytes, macrophages, and dendritic cells. Science 2010 327 5966 656 661 2-s2.0-76249095169 10.1126/science.1178331
22. Karre K., Ljunggren H. G., Piontek G., Kiessling R., Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 1986 319 6055 675 678 2-s2.0-0022616253 (Pubitemid 16119452)
23. Raulet D. H., Vance R. E., McMahon C. W., Regulation of the natural killer cell receptor repertoire. Annual Review of Immunology 2001 19 291 330 2-s2.0-0035056004 10.1146/annurev.immunol.19.1.291 (Pubitemid 32368038)
24. Langers I., Renoux V. M., Thiry M., Delvenne P., Jacobs N., Natural killer cells: role in local tumor growth and metastasis. Biologics: Targets & Therapy 2012 6 73 82
25. + T helper cells: functional plasticity and differential sensitivity to regulatory T cell-mediated regulation. Clinical and Experimental Immunology 2010 159 2 137 147 2-s2.0-72949104568 10.1111/j.1365-2249.2009.04040.x
26. Wing J. B., Sakaguchi S., Multiple treg suppressive modules and their adaptability. Frontiers in Immunology 2012 3 178
27. Weaver C. T., Harrington L. E., Mangan P. R., Gavrieli M., Murphy K. M., Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 2006 24 6 677 688 2-s2.0-33744984785 10.1016/j.immuni.2006.06.002 (Pubitemid 43867371)
28. Whitfield J. R., Soucek L., Tumor microenvironment: becoming sick of Myc. Cellular and Molecular Life Sciences 2012 69 931 934
29. Fuentes-Pananá E., Camorlinga-Ponce M., Maldonado-Bernal C., Infection, inflammation and gastric cancer. Salud Publica de Mexico 2009 51 5 427 433 2-s2.0-70349644981
30. Colotta F., Allavena P., Sica A., Garlanda C., Mantovani A., Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009 30 7 1073 1081 2-s2.0-67650151005 10.1093/carcin/bgp127
31. Fiaschi T., Chiarugi P., Oxidative stress, tumor microenvironment, and metabolic reprogramming: a diabolic liaison. International Journal of Cell Biology 2012 2012 8 10.1155/2012/762825 762825
32. Harada A., Sekido N., Akahoshi T., Wada T., Mukaida N., Matsushima K., Essential involvement of interleukin-8 (IL-8) in acute inflammation. Journal of Leukocyte Biology 1994 56 5 559 564 2-s2.0-0027988669 (Pubitemid 24348812)
33. Johansson M., Denardo D. G., Coussens L. M., Polarized immune responses differentially regulate cancer development. Immunological Reviews 2008 222 1 145 154 2-s2.0-41149136843 10.1111/j.1600-065X.2008.00600.x (Pubitemid 351430362)
34. Grivennikov S. I., Greten F. R., Karin M., Immunity, inflammation, and cancer. Cell 2010 140 6 883 899 2-s2.0-77950346282 10.1016/j.cell.2010.01.025
35. Xu Q., Wang L., Li H., Han Q., Li J., Qu X., Huang S., Zhao R. C., Mesenchymal stem cells play a potential role in regulating the establishment and maintenance of epithelial-mesenchymal transition in MCF7 human breast cancer cells by paracrine and induced autocrine TGF-beta. International Journal of Oncology 2012 41 3 10.3892/ijo.2012.1541
36. Wang H., Wu J., Zhang Y., Xue X., Tang D., Yuan Z., Chen M., Wei J., Zhang J., Miao Y., Transforming growth factor beta-induced epithelial- mesenchymal transition increases cancer stem-like cells in the PANC-1 cell line. Oncology Letters 2012 3 229 233
37. Malinowsky K., Raychaudhuri M., Buchner T., Thulke S., Wolff C., Hofler H., Becker K. F., Avril S., Common protein biomarkers assessed by reverse phase protein arrays show considerable intratumoral heterogeneity in breast cancer tissues. PloS One 2012 7 e40285
38. Schillaci R., Guzman P., Cayrol F., Beguelin W., Diaz Flaque M. C., Proietti C. J., Pineda V., Palazzi J., Frahm I., Charreau E. H., Maronna E., Roa J. C., Elizalde P. V., Clinical relevance of ErbB-2/HER2 nuclear expression in breast cancer. BMC Cancer 2012 12 article 74 10.1186/1471-2407-12-74
39. Giannios J., Ioannidou-Mouzaka L., Molecular aspects of breast and ovarian cancer. European Journal of Gynaecological Oncology 1997 18 5 387 393 2-s2.0-0030771722 (Pubitemid 27437749)
40. Tindall E. A., Severi G., Hoang H. N., Southey M. C., English D. R., Hopper J. L., Giles G. G., Hayes V. M., Interleukin-6 promoter variants, prostate cancer risk, and survival. The Prostate 2012 72 16 1701 1707 10.1002/pros.22557
41. Wang Y., Li L., Guo X., Jin X., Sun W., Zhang X., Xu R. C., Interleukin-6 signaling regulates anchorage-independent growth, proliferation, adhesion and invasion in human ovarian cancer cells. Cytokine 2012 59 228 236 10.1016/j.cyto.2012.04.020
42. Mantovani A., Sica A., Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Current Opinion in Immunology 2010 22 2 231 237 2-s2.0-77950944395 10.1016/j.coi.2010.01.009
43. Gabrilovich D. I., Ostrand-Rosenberg S., Bronte V., Coordinated regulation of myeloid cells by tumours. Nature Reviews Immunology 2012 12 253 268 10.1038/nri3175
44. Ben-Neriah Y., Karin M., Inflammation meets cancer, with NF-kappaB as the matchmaker. Nature Immunology 2011 12 715 723
45. Greten F. R., Eckmann L., Greten T. F., Park J. M., Li Z. W., Egan L. J., Kagnoff M. F., Karin M., IKK β links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004 118 3 285 296 2-s2.0-4043088499 10.1016/j.cell.2004.07.013 (Pubitemid 39061110)
46. Nehra R., Riggins R. B., Shajahan A. N., Zwart A., Crawford A. C., Clarke R., BCL2 and CASP8 regulation by NF- B differentially affect mitochondrial function and cell fate in antiestrogen-sensitive and -resistant breast cancer cells. The FASEB Journal 2010 24 6 2040 2055 2-s2.0-77953488930 10.1096/fj.09-138305
47. Baldwin A. S., Control of oncogenesis and cancer therapy resistance by the transcription factor NF- B. Journal of Clinical Investigation 2001 107 3 241 246 2-s2.0-0035137882 (Pubitemid 32157954)
48. Sheppard K., Kinross K. M., Solomon B., Pearson R. B., Phillips W. A., Targeting PI3 kinase/AKT/mTOR signaling in cancer. Critical Reviews in Oncogenesis 2012 17 69 95
49. Trojan L., Thomas D., Knoll T., Grobholz R., Alken P., Michel M. S., Expression of pro-angiogenic growth factors VEGF, EGF and bFGF and their topographical relation to neovascularisation in prostate cancer. Urological Research 2004 32 2 97 103 2-s2.0-3142704316 10.1007/s00240-003-0383-5 (Pubitemid 38915398)
50. Pugh C. W., Ratcliffe P. J., Regulation of angiogenesis by hypoxia: role of the HIF system. Nature Medicine 2003 9 6 677 684 2-s2.0-0038037735 10.1038/nm0603-677 (Pubitemid 36749216)
51. Shen K., Ji L., Gong C., Ma Y., Yang L., Fan Y., Hou M., Wang Z., Notoginsenoside Ft1 promotes angiogenesis via HIF-1 α mediated VEGF secretion and the regulation of PI3K/AKT and Raf/MEK/ERK signaling pathways. Biochemical Pharmacology 2012 84 6 784 792 10.1016/j.bcp.2012.05.024
52. Hicklin D. J., Ellis L. M., Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. Journal of Clinical Oncology 2005 23 5 1011 1027 2-s2.0-14644440555 10.1200/JCO.2005.06.081 (Pubitemid 46202320)
53. Wels J., Kaplan R. N., Rafii S., Lyden D., Migratory neighbors and distant invaders: tumor-associated niche cells. Genes and Development 2008 22 5 559 574 2-s2.0-40349098612 10.1101/gad.1636908 (Pubitemid 351342429)
54. Wang T. B., Chen Z. G., Wei X. Q., Wei B., Dong W. G., Serum vascular endothelial growth factor-C and lymphoangiogenesis are associated with the lymph node metastasis and prognosis of patients with colorectal cancer. ANZ Journal of Surgery 2011 81 694 699 10.1111/j.1445-2197.2010.05539.x
55. Talbot L. J., Bhattacharya S. D., Kuo P. C., Epithelial-mesenchymal transition, the tumor microenvironment, and metastatic behavior of epithelial malignancies. International Journal of Biochemistry and Molecular Biology 2012 3 117 136
56. Gunasinghe N. P., Wells A., Thompson E. W., Hugo H. J., Mesenchymal-epithelial transition (MET) as a mechanism for metastatic colonisation in breast cancer. Cancer Metastasis Reviews 2012 31 3-4 469 478 10.1007/s10555-012-9377-5
57. Onitilo A. A., Aryal G., Engel J. M., Hereditary diffuse Gastric cancer: a family diagnosis and treatment. Clinical Medicine & Research 2012 10.3121/cmr.2012.1071
58. Masciari S., Larsson N., Senz J., Boyd N., Kaurah P., Kandel M. J., Harris L. N., Pinheiro H. C., Troussard A., Miron P., Tung N., Oliveira C., Collins L., Schnitt S., Garber J. E., Huntsman D., Germline E-cadherin mutations in familial lobular breast cancer. Journal of Medical Genetics 2007 44 11 726 731 2-s2.0-36348986039 10.1136/jmg.2007.051268 (Pubitemid 350155461)
59. Huang F. Y., Chan A. O., Rashid A., Wong D. K., Cho C. H., Yuen M. F., Helicobacter pylori induces promoter methylation of E-cadherin via interleukin-1 β activation of nitric oxide production in gastric cancer cells. Cancer 2012 118 20 4969 4980 10.1002/cncr.27519
60. Hoy B., Geppert T., Boehm M., Reisen F., Plattner P., Gadermaier G., Sewald N., Ferreira F., Briza P., Schneider G., Backert S., Wessler S., Distinct roles of secreted HtrA proteases from gram-negative pathogens in cleaving the junctional protein and tumor suppressor E-cadherin. The Journal of Biological Chemistry 2012 287 10115 10120 10.1074/jbc.C111.333419
61. Murata-Kamiya N., Kurashima Y., Teishikata Y., Yamahashi Y., Saito Y., Higashi H., Aburatani H., Akiyama T., Peek R. M., Azuma T., Hatakeyama M., Helicobacter pylori CagA interacts with E-cadherin and deregulates the β -catenin signal that promotes intestinal transdifferentiation in gastric epithelial cells. Oncogene 2007 26 32 4617 4626 2-s2.0-34447519946 10.1038/sj.onc.1210251 (Pubitemid 47067401)
62. Mutoh H., Sakurai S., Satoh K., Osawa H., Hakamata Y., Takeuchi T., Sugano K., Cdx1 induced intestinal metaplasia in the transgenic mouse stomach: comparative study with Cdx2 transgenic mice. Gut 2004 53 10 1416 1423 2-s2.0-4644346431 10.1136/gut.2003.032482 (Pubitemid 39265258)
63. Saito Y., Murata-Kamiya N., Hirayama T., Ohba Y., Hatakeyama M., Conversion of Helicobacter pylori CagA from senescence inducer to oncogenic driver through polarity-dependent regulation of p21. The Journal of Experimental Medicine 2010 207 10 2157 2174 2-s2.0-77957737610 10.1084/jem.20100602
64. Hussain F., Morton P. E., Snippe M., Sullivan J., Farmer C., Martin-Fernandez M. L., Parsons M., Santis G., CAR modulates E-cadherin dynamics in the presence of adenovirus type 5. PLoS One 2011 6 8 2-s2.0-79961139374 10.1371/journal.pone.0023056 e23056
65. Matthews K., Leong C. M., Baxter L., Inglis E., Yun K., Bäckström B. T., Doorbar J., Hibma M., Depletion of Langerhans cells in human papillomavirus type 16-infected skin is associated with E6-mediated down regulation of E-cadherin. Journal of Virology 2003 77 15 8378 8385 2-s2.0-0038107894 10.1128/JVI.77.15.8378-8385.2003 (Pubitemid 36871466)
66. Lee J. O., Kwun H. J., Jung J. K., Choi K. H., Min D. S., Jang K. L., Hepatitis B virus X protein represses E-cadherin expression via activation of DNA methyltransferase 1. Oncogene 2005 24 44 6617 6625 2-s2.0-27144448810 10.1038/sj.onc.1208827 (Pubitemid 41486792)
67. Lee J. M., Dedhar S., Kalluri R., Thompson E. W., The epithelial-mesenchymal transition: new insights in signaling, development, and disease. Journal of Cell Biology 2006 172 7 973 981 2-s2.0-33645302628 10.1083/jcb.200601018
68. Jing Y., Han Z., Zhang S., Liu Y., Wei L., Epithelial-Mesenchymal transition in tumor microenvironment. Cell & Bioscience 2011 1 article 29 10.1186/2045-3701-1-29
69. López-Otín C., Hunter T., The regulatory crosstalk between kinases and proteases in cancer. Nature Reviews Cancer 2010 10 4 278 292 2-s2.0-77950012622 10.1038/nrc2823
70. Mason S. D., Joyce J. A., Proteolytic networks in cancer. Trends in Cell Biology 2011 21 4 228 237 2-s2.0-79953163995 10.1016/j.tcb.2010.12.002
71. Bergers G., Brekken R., McMahon G., Vu T. H., Itoh T., Tamaki K., Tanzawa K., Thorpe P., Itohara S., Werb Z., Hanahan D., Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biology 2000 2 10 737 744 2-s2.0-0000391746 10.1038/35036374
72. Victor B. C., Anbalagan A., Mohamed M. M., Sloane B. F., Cavallo-Medved D., Inhibition of cathepsin B activity attenuates extracellular matrix degradation and inflammatory breast cancer invasion. Breast Cancer Research 2011 13 article R115
73. Duffy M. J., Maguire T. M., McDermott E. W., O'Higgins N., Urokinase plasminogen activator: a prognostic marker in multiple types of cancer. Journal of Surgical Oncology 1999 71 130 135 10.1002/(SICI)1096-9098(199906)71:2<130: :AID-JSO14>3.0.CO;2-9 (Pubitemid 29288493)
74. Duffy M. J., Urokinase-type plasminogen activator: a potent marker of metastatic potential in human cancers. Biochemical Society Transactions 2002 30 2 207 210 2-s2.0-0036547696
75. Jelisavac-Cosic S., Sirotkovic-Skerlev M., Kulic A., Jakic-Razumovic J., Kovac Z., Vrbanec D., Prognostic significance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor (PAI-1) in patients with primary invasive ductal breast carcinoma-a 7.5-year follow-up study. Tumori 2011 97 532 539
76. Whitley B. R., Palmieri D., Twerdi C. D., Church F. C., Expression of active plasminogen activator inhibitor-1 reduces cell migration and invasion in breast and gynecological cancer cells. Experimental Cell Research 2004 296 2 151 162 2-s2.0-2442545196 10.1016/j.yexcr.2004.02.022 (Pubitemid 38624637)
77. Magdolen V., Krüger A., Sato S., Nagel J., Sperl S., Reuning U., Rettenberger P., Magdolen U., Schmitt M., Inhibition of the tumor-associated urokinase-type plasminogen activation system: effects of high-level synthesis of soluble urokinase receptor in ovarian and breast cancer cells in vitro and in vivo. Recent Results in Cancer Research 2003 162 43 63 2-s2.0-0042783126
78. Giraudo E., Inoue M., Hanahan D., An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. Journal of Clinical Investigation 2004 114 5 623 633 2-s2.0-4944239035 10.1172/JCI200422087 (Pubitemid 39578752)
79. Coussens L. M., Tinkle C. L., Hanahan D., Werb Z., MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000 103 3 481 490 2-s2.0-0034721666
80. Coleman R. E., Bisphosphonates in breast cancer. Annals of Oncology 2005 16 5 687 695 2-s2.0-20044389681 10.1093/annonc/mdi162 (Pubitemid 40767087)
81. Tan W., Zhang W., Strasner A., Grivennikov S., Cheng J. Q., Hoffman R. M., Karin M., Tumour-infiltrating regulatory T cells stimulate mammary cancermetastasis through RANKL-RANK signalling. Nature 2011 470 7335 548 553 2-s2.0-79952193038 10.1038/nature09707
82. Kaplan R. N., Riba R. D., Zacharoulis S., Bramley A. H., Vincent L., Costa C., MacDonald D. D., Jin D. K., Shido K., Kerns S. A., Zhu Z., Hicklin D., Wu Y., Port J. L., Altorki N., Port E. R., Ruggero D., Shmelkov S. V., Jensen K. K., Rafii S., Lyden D., VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005 438 7069 820 827 2-s2.0-28644432204 10.1038/nature04186 (Pubitemid 41753060)
83. Shokeen M., Zheleznyak A., Wilson J. M., Jiang M., Liu R., Ferdani R., Lam K. S., Schwarz J. K., Anderson C. J., Molecular imaging of very late antigen-4 (alpha4beta1 integrin) in the premetastatic niche. Journal of Nuclear Medicine 2012 53 779 786
84. Bolat F., Kayaselcuk F., Nursal T. Z., Yagmurdur M. C., Bal N., Demirhan B., Microvessel density, VEGF expression, and tumor-associated macrophages in breast tumors: correlations with prognostic parameters. Journal of Experimental and Clinical Cancer Research 2006 25 3 365 372 2-s2.0-33751098783 (Pubitemid 44763728)
85. Osinsky S., Bubnovskaya L., Ganusevich I., Kovelskaya A., Gumenyuk L., Olijnichenko G., Merentsev S., Hypoxia, tumour-associated macrophages, microvessel density, VEGF and matrix metalloproteinases in human gastric cancer: interaction and impact on survival. Clinical and Translational Oncology 2011 13 2 133 138 2-s2.0-79958010073 10.1007/s12094-011-0630-0
86. de Visser K. E., Eichten A., Coussens L. M., Paradoxical roles of the immune system during cancer development. Nature Reviews Cancer 2006 6 1 24 37 2-s2.0-30144443269 10.1038/nrc1782 (Pubitemid 43053650)
87. Rabenhorst A., Schlaak M., Heukamp L. C., Forster A., Theurich S., von Bergwelt-Baildon M., Buttner R., Kurschat P., Mauch C., Roers A., Hartmann K., Mast cells play a protumorigenic role in primary cutaneous lymphoma. Blood 2012 120 10 2042 2054 10.1182/blood-2012-03-415638
88. Priceman S. J., Sung J. L., Shaposhnik Z., Burton J. B., Torres-Collado A. X., Moughon D. L., Johnson M., Lusis A. J., Cohen D. A., Iruela-Arispe M. L., Wu L., Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. Blood 2010 115 7 1461 1471 2-s2.0-77949900433 10.1182/blood-2009-08-237412
89. Lin E. Y., Nguyen A. V., Russell R. G., Pollard J. W., Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. The Journal of Experimental Medicine 2001 193 6 727 740 2-s2.0-0035911221 10.1084/jem.193.6.727 (Pubitemid 32524466)
90. Patsialou A., Wyckoff J., Wang Y., Goswami S., Stanley E. R., Condeelis J. S., Invasion of human breast cancer cells in vivo requires both paracrine and autocrine loops involving the colony-stimulating factor-1 receptor. Cancer Research 2009 69 24 9498 9506 2-s2.0-73649122504 10.1158/0008-5472.CAN-09-1868
91. Agarwal S., Reddy G. V., Reddanna P., Eicosanoids in inflammation and cancer: the role of COX-2. Expert Review of Clinical Immunology 2009 5 2 145 165 2-s2.0-70349914077 10.1586/1744666X.5.2.145
92. Wang D., Dubois R. N., Eicosanoids and cancer. Nature Reviews Cancer 2010 10 3 181 193 2-s2.0-77649179672 10.1038/nrc2809
93. Cuzick J., Otto F., Baron J. A., Brown P. H., Burn J., Greenwald P., Jankowski J., La Vecchia C., Meyskens F., Senn H. J., Thun M., Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. The Lancet Oncology 2009 10 5 501 507 2-s2.0-65349152488 10.1016/S1470-2045(09)70035-X
94. Ferrandez A., Piazuelo E., Castells A., Aspirin and the prevention of colorectal cancer. Best Practice & Research. Clinical Gastroenterology 2012 26 2 185 195 10.1016/j.bpg.2012.01.009
95. Garaude J., Kent A., van Rooijen N., Blander J. M., Simultaneous targeting of toll- and nod-like receptors induces effective tumor-specific immune responses. Science Translational Medicine 2012 4 120ra116
96. Pollard J. W., Trophic macrophages in development and disease. Nature Reviews Immunology 2009 9 4 259 270 2-s2.0-63149088164 10.1038/nri2528
97. Steidl C., Lee T., Shah S. P., Farinha P., Han G., Nayar T., Delaney A., Jones S. J., Iqbal J., Weisenburger D. D., Bast M. A., Rosenwald A., Muller-Hermelink H. K., Rimsza L. M., Campo E., Delabie J., Braziel R. M., Cook J. R., Tubbs R. R., Jaffe E. S., Lenz G., Connors J. M., Staudt L. M., Chan W. C., Gascoyne R. D., Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. The New England Journal of Medicine 2010 362 10 875 885 2-s2.0-77949345555 10.1056/NEJMoa0905680
98. Subimerb C., Pinlaor S., Khuntikeo N., Leelayuwat C., Morris A., McGrath M. S., Wongkham S., Tissue invasive macrophage density is correlated with prognosis in cholangiocarcinoma. Molecular Medicine Reports 2010 3 4 597 605 2-s2.0-77955736266 10.3892/mmr-00000303
99. Kurahara H., Takao S., Maemura K., Mataki Y., Kuwahata T., Maeda K., Sakoda M., Iino S., Ishigami S., Ueno S., Shinchi H., Natsugoe S., M2-polarized tumor-associated macrophage infiltration of regional lymph nodes is associated with nodal lymphangiogenesis and occult nodal involvement in pN0 pancreatic cancer. Pancreas 2013 42 1 155 159 10.1097/MPA.0b013e318254f2d1
100. Mahmoud S. M., Lee A. H., Paish E. C., Macmillan R. D., Ellis I. O., Green A. R., Tumour-infiltrating macrophages and clinical outcome in breast cancer. Journal of Clinical Pathology 2012 65 2 159 163 10.1136/jclinpath-2011- 200355
101. Wei Q., Fang W., Ye L., Shen L., Zhang X., Fei X., Chen X., Li X., Xiao J., Ning G., Density of tumor-associated macrophages correlates with lymph node metastasis in papillary thyroid carcinoma. Thyroid 2012 22 9 905 910
102. Qian B. Z., Pollard J. W., Macrophage diversity enhances tumor progression and metastasis. Cell 2010 141 1 39 51 2-s2.0-77950950894 10.1016/j.cell.2010.03.014
103. Morandi A., Barbetti V., Riverso M., Dello Sbarba P., Rovida E., The colony-stimulating factor-1 (CSF-1) receptor sustains ERK1/2 activation and proliferation in breast cancer cell lines. PloS One 2011 6 11 10.1371/journal.pone.0027450 e27450
104. Lee Y., Chittezhath M., Andre V., Zhao H., Poidinger M., Biondi A., D'Amico G., Biswas S. K., Protumoral role of monocytes in human B-cell precursor acute lymphoblastic leukemia: involvement of the chemokine CXCL10. Blood 2012 119 1 227 237 10.1182/blood-2011-06-357442
105. Hao N. B., Lu M. H., Fan Y. H., Cao Y. L., Zhang Z. R., Yang S. M., Macrophages in tumor microenvironments and the progression of tumors. Clinical & Developmental Immunology 2012 2012 11 10.1155/2012/948098 948098
106. Smith P. D., Smythies L. E., Shen R., Greenwell-Wild T., Gliozzi M., Wahl S. M., Intestinal macrophages and response to microbial encroachment. Mucosal Immunology 2011 4 1 31 42 2-s2.0-78650807608 10.1038/mi.2010.66
107. Weisser S. B., Brugger H. K., Voglmaier N. S., McLarren K. W., van Rooijen N., Sly L. M., SHIP-deficient, alternatively activated macrophages protect mice during DSS-induced colitis. Journal of Leukocyte Biology 2011 90 3 483 492 10.1189/jlb.0311124
108. Wahl S. M., Chen W., Transforming growth factor β -induced regulatory T cells referee inflammatory and autoimmune diseases. Arthritis Research and Therapy 2005 7 2 62 68 2-s2.0-15944387363 10.1186/ar1504 (Pubitemid 40439440)
109. + T cells. Nature Immunology 2007 8 12 1353 1362 2-s2.0-36248976097 10.1038/ni1536 (Pubitemid 350131172)
110. + T cells. Journal of Immunology 2005 175 3 1483 1490 2-s2.0-22544436066 (Pubitemid 41023048)
111. Condeelis J., Pollard J. W., Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006 124 2 263 266 2-s2.0-31044433663 10.1016/j.cell.2006.01.007 (Pubitemid 43121975)
112. Rogers T. L., Holen I., Tumour macrophages as potential targets of bisphosphonates. Journal of Translational Medicine 2011 9 article 177 10.1186/1479-5876-9-177
113. Bellocq A., Antoine M., Flahault A., Philippe C., Crestani B., Bernaudin J. F., Mayaud C., Milleron B., Baud L., Cadranel J., Neutrophil alveolitis in bronchioloalveolar carcinoma: induction by tumor-derived interleukin-8 and relation to clinical outcome. American Journal of Pathology 1998 152 1 83 92 2-s2.0-0031975315 (Pubitemid 28028049)
114. Pekarek L. A., Starr B. A., Toledano A. Y., Schreiber H., Inhibition of tumor growth by elimination of granulocytes. The Journal of Experimental Medicine 1995 181 1 435 440 2-s2.0-0028928899 10.1084/jem.181.1.435
115. Jensen H. K., Donskov F., Marcussen N., Nordsmark M., Lundbeck F., von der Maase H., Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. Journal of Clinical Oncology 2009 27 28 4709 4717 2-s2.0-70350455089 10.1200/JCO.2008.18.9498
116. Wislez M., Rabbe N., Marchal J., Milleron B., Crestani B., Mayaud C., Antoine M., Soler P., Cadranel J., Hepatocyte growth factor production by neutrophils infiltrating bronchioloalveolar subtype pulmonary adenocarcinoma: role in tumor progression and death. Cancer Research 2003 63 6 1405 1412 2-s2.0-0037444169 (Pubitemid 36348724)
117. + granulocytes. Proceedings of the National Academy of Sciences of the United States of America 2010 107 50 21248 21255 2-s2.0-78650722060 10.1073/pnas.1015855107
118. Houghton A. M., Rzymkiewicz D. M., Ji H., Gregory A. D., Egea E. E., Metz H. E., Stolz D. B., Land S. R., Marconcini L. A., Kliment C. R., Jenkins K. M., Beaulieu K. A., Mouded M., Frank S. J., Wong K. K., Shapiro S. D., Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth. Nature Medicine 2010 16 2 219 223 2-s2.0-76249101753 10.1038/nm.2084
119. Conti P., Castellani M. L., Kempuraj D., Salini V., Vecchiet J., Tetè S., Mastrangelo F., Perrella A., De Lutiis M. A., Tagen M., Theoharides T. C., Role of mast cells in tumor growth. Annals of Clinical and Laboratory Science 2007 37 4 315 322 2-s2.0-36148964034 (Pubitemid 350105931)
120. Huang B., Lei Z., Zhang G. M., Li D., Song C., Li B., Liu Y., Yuan Y., Unkeless J., Xiong H., Feng Z. H., SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment. Blood 2008 112 4 1269 1279 2-s2.0-51649123035 10.1182/blood-2008-03-147033
121. Norrby K., Mast cells and angiogenesis. APMIS 2002 110 5 355 371 2-s2.0-0036085728 10.1034/j.1600-0463.2002.100501.x (Pubitemid 34666551)
122. Coussens L. M., Raymond W. W., Bergers G., Laig-Webster M., Behrendtsen O., Werb Z., Caughey G. H., Hanahan D., Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes and Development 1999 13 11 1382 1397 2-s2.0-0033151608 (Pubitemid 29270244)
123. Ribatti D., Crivellato E., The controversial role of mast cells in tumor growth. International Review of Cell and Molecular Biology 2009 275 89 131 2-s2.0-66149120295 10.1016/S1937-6448(09)75004-X
124. Wasiuk A., de Vries V. C., Hartmann K., Roers A., Noelle R. J., Mast cells as regulators of adaptive immunity to tumours. Clinical and Experimental Immunology 2009 155 2 140 146 2-s2.0-58149279371 10.1111/j.1365-2249.2008.03840. x
125. Mancino A., Schioppa T., Larghi P., Pasqualini F., Nebuloni M., Chen I. H., Sozzani S., Austyn J. M., Mantovani A., Sica A., Divergent effects of hypoxia on dendritic cell functions. Blood 2008 112 9 3723 3734 2-s2.0-55749095015 10.1182/blood-2008-02-142091
126. Elia A. R., Cappello P., Puppo M., Fraone T., Vanni C., Eva A., Musso T., Novelli F., Varesio L., Giovarelli M., Human dendritic cells differentiated in hypoxia down-modulate antigen uptake and change their chemokine expression profile. Journal of Leukocyte Biology 2008 84 6 1472 1482 2-s2.0-57149114568 10.1189/jlb.0208082 (Pubitemid 352774482)
127. Yang M., Ma C., Liu S., Shao Q., Gao W., Song B., Sun J., Xie Q., Zhang Y., Feng A., Liu Y., Hu W., Qu X., HIF-dependent induction of adenosine receptor A2b skews human dendritic cells to a Th2-stimulating phenotype under hypoxia. Immunology and Cell Biology 2010 88 2 165 171 2-s2.0-77149154994 10.1038/icb.2009.77
128. Scarlett U. K., Rutkowski M. R., Rauwerdink A. M., Fields J., Escovar-Fadul X., Baird J., Cubillos-Ruiz J. R., Jacobs A. C., Gonzalez J. L., Weaver J., Fiering S., Conejo-Garcia J. R., Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. The Journal of Experimental Medicine 2012 209 3 495 506 10.1084/jem.20111413
129. Novitskiy S. V., Ryzhov S., Zaynagetdinov R., Goldstein A. E., Huang Y., Tikhomirov O. Y., Blackburn M. R., Biaggioni I., Carbone D. P., Feoktistov I., Dikov M. M., Adenosine receptors in regulation of dendritic cell differentiation and function. Blood 2008 112 5 1822 1831 2-s2.0-52649138296 10.1182/blood-2008-02-136325
130. Tan T. T., Coussens L. M., Humoral immunity, inflammation and cancer. Current Opinion in Immunology 2007 19 2 209 216 2-s2.0-33847628325 10.1016/j.coi.2007.01.001 (Pubitemid 46356960)
131. DeNardo D. G., Coussens L. M., Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Research 2007 9 4 212 2-s2.0-40349094954
132. Zapata J. M., Llobet D., Krajewska M., Lefebvre S., Kress C. L., Reed J. C., Lymphocyte-specific TRAF3 transgenic mice have enhanced humoral responses and develop plasmacytosis, autoimmunity, inflammation, and cancer. Blood 2009 113 19 4595 4603 2-s2.0-66549089712 10.1182/blood-2008-07-165456
133. de Visser K. E., Korets L. V., Coussens L. M., De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 2005 7 5 411 423 2-s2.0-19344365408 10.1016/j.ccr.2005.04.014 (Pubitemid 40719125)
134. Talmadge J. E., Donkor M., Scholar E., Inflammatory cell infiltration of tumors: Jekyll or Hyde. Cancer and Metastasis Reviews 2007 26 3-4 373 400 2-s2.0-36148960830 10.1007/s10555-007-9072-0 (Pubitemid 350115102)
135. Schreiber R. D., Old L. J., Smyth M. J., Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011 331 6024 1565 1570 2-s2.0-79953151458 10.1126/science.1203486
136. Vesely M. D., Kershaw M. H., Schreiber R. D., Smyth M. J., Natural innate and adaptive immunity to cancer. Annual Review of Immunology 2011 29 235 271 2-s2.0-79953059789 10.1146/annurev-immunol-031210-101324
137. Josefowicz S. Z., Lu L. F., Rudensky A. Y., Regulatory T cells: mechanisms of differentiation and function. Annual Review of Immunology 2012 30 531 564 10.1146/annurev.immunol.25.022106.141623
138. Onizuka S., Tawara I., Shimizu J., Sakaguchi S., Fujita T., Nakayama E., Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody. Cancer Research 1999 59 13 3128 3133 2-s2.0-0033168037 (Pubitemid 29316012)
139. Driessler F., Venstrom K., Sabat R., Asadullah K., Schottelius A. J., Molecular mechanisms of interleukin-10-mediated inhibition of NF- B activity: a role for p50. Clinical and Experimental Immunology 2004 135 1 64 73 2-s2.0-0347949510 10.1111/j.1365-2249.2004.02342.x (Pubitemid 38067929)
140. Ouyang W., Rutz S., Crellin N. K., Valdez P. A., Hymowitz S. G., Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annual Review of Immunology 2011 29 71 109 2-s2.0-79953048089 10.1146/annurev-immunol-031210-101312
141. Prieto P. A., Yang J. C., Sherry R. M., Hughes M. S., Kammula U. S., White D. E., Levy C. L., Rosenberg S. A., Phan G. Q., CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clinical Cancer Research 2012 18 2039 2047 10.1158/1078-0432.CCR-11-1823
142. Zhou G., Levitsky H., Towards curative cancer immunotherapy: overcoming posttherapy tumor escape. Clinical and Developmental Immunology 2012 2012 12 10.1155/2012/124187 124187
143. Gabrilovich D. I., Nagaraj S., Myeloid-derived suppressor cells as regulators of the immune system. Nature Reviews Immunology 2009 9 3 162 174 2-s2.0-61349100687 10.1038/nri2506
144. + cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor. Clinical Cancer Research 1995 1 1 95 103 2-s2.0-0028942668
145. + progenitor cells by tumor-derived vascular endothelial cell growth factor. Clinical and Experimental Metastasis 1999 17 10 881 888 2-s2.0-0033757517 10.1023/A:1006708607666
146. Young M. R. I., Wright M. A., Myelopoiesis-associated immune suppressor cells in mice bearing metastatic Lewis lung carcinoma tumors: γ interferon plus tumor necrosis factor α synergistically reduces immune suppressor and tumor growth-promoting activities of bone marrow cells and diminishes tumor recurrence and metastasis. Cancer Research 1992 52 22 6335 6340 2-s2.0-0026471974
147. Peranzoni E., Zilio S., Marigo I., Dolcetti L., Zanovello P., Mandruzzato S., Bronte V., Myeloid-derived suppressor cell heterogeneity and subset definition. Current Opinion in Immunology 2010 22 2 238 244 2-s2.0-77951258918 10.1016/j.coi.2010.01.021
148. Greten T. F., Manns M. P., Korangy F., Myeloid derived suppressor cells in human diseases. International Immunopharmacology 2011 11 7 802 806 2-s2.0-79955723632 10.1016/j.intimp.2011.01.003
149. Filipazzi P., Valenti R., Huber V., Pilla L., Canese P., Iero M., Castelli C., Mariani L., Parmiani G., Rivoltini L., Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. Journal of Clinical Oncology 2007 25 18 2546 2553 2-s2.0-34447258415 10.1200/JCO.2006.08.5829 (Pubitemid 47041228)
150. Waight J. D., Hu Q., Miller A., Liu S., Abrams S. I., Tumor-derived G-CSF facilitates neoplastic growth through a granulocytic myeloid-derived suppressor cell-dependent mechanism. PloS One 2011 6 e27690
151. Stairs D. B., Bayne L. J., Rhoades B., Vega M. E., Waldron T. J., Kalabis J., Klein-Szanto A., Lee J. S., Katz J. P., Diehl J. A., Reynolds A. B., Vonderheide R. H., Rustgi A. K., Deletion of p120-catenin results in a tumor microenvironment with inflammation and cancer that establishes it as a tumor suppressor gene. Cancer Cell 2011 19 4 470 483 2-s2.0-79953736599 10.1016/j.ccr.2011.02.007
152. Dilek N., Vuillefroy de Silly R., Blancho G., Vanhove B., Myeloid-derived suppressor cells: mechanisms of action and recent advances in their role in transplant tolerance. Frontiers in Immunology 2012 3 208 10.3389/fimmu.2012. 00208
153. Nagaraj S., Gabrilovich D. I., Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Research 2008 68 8 2561 2563 2-s2.0-42349094504 10.1158/0008-5472.CAN-07-6229 (Pubitemid 351556251)
154. Ostrand-Rosenberg S., Sinha P., Myeloid-derived suppressor cells: linking inflammation and cancer. Journal of Immunology 2009 182 8 4499 4506 2-s2.0-65249138393 10.4049/jimmunol.0802740
155. Sica A., Bronte V., Altered macrophage differentiation and immune dysfunction in tumor development. Journal of Clinical Investigation 2007 117 5 1155 1166 2-s2.0-34248172324 10.1172/JCI31422 (Pubitemid 46718400)
156. + T cells. Journal of Immunology 2009 183 2 937 944 2-s2.0-70249140303 10.4049/jimmunol.0804253
157. Molon B., Ugel S., Del Pozzo F., Soldani C., Zilio S., Avella D., De Palma A., Mauri P., Monegal A., Rescigno M., Savino B., Colombo P., Jonjic N., Pecanic S., Lazzarato L., Fruttero R., Gasco A., Bronte V., Viola A., Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. The Journal of Experimental Medicine 2011 208 10 1949 1962 10.1084/jem.20101956
158. Pan P. Y., Ma G., Weber K. J., Ozao-Choy J., Wang G., Yin B., Divino C. M., Chen S. H., Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Research 2010 70 1 99 108 2-s2.0-75149179545 10.1158/0008-5472.CAN-09-1882
159. + immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Research 2006 66 2 1123 1131 2-s2.0-31544446571 10.1158/0008-5472.CAN-05-1299 (Pubitemid 43165981)
160. - T cells. Journal of Leukocyte Biology 2012 92 5 987 997 10.1189/jlb.0911465
161. Li H., Han Y., Guo Q., Zhang M., Cao X., Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF- β 1. Journal of Immunology 2009 182 1 240 249 2-s2.0-59849126377
162. + myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clinical Cancer Research 2005 11 18 6713 6721 2-s2.0-25144466458 10.1158/1078-0432.CCR-05-0883 (Pubitemid 41339014)
163. + immature myeloid cells into both suppressor macrophages and immunostimulatory dendritic cells. Biomedical Research 2009 30 1 7 15 2-s2.0-66749149867
164. Corzo C. A., Condamine T., Lu L., Cotter M. J., Youn J. I., Cheng P., Cho H. I., Celis E., Quiceno D. G., Padhya T., McCaffrey T. V., McCaffrey J. C., Gabrilovich D. I., HIF-1 α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. The Journal of Experimental Medicine 2010 207 11 2439 2453 2-s2.0-78149330949 10.1084/jem.20100587
165. + cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 2004 6 4 409 421 2-s2.0-5444225991 10.1016/j.ccr.2004.08.031 (Pubitemid 39361441)
166. Toh B., Wang X., Keeble J., Sim W. J., Khoo K., Wong W. C., Kato M., Prevost-Blondel A., Thiery J. P., Abastado J. P., Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor. PLoS Biology 2011 9 e1001162
167. Grivennikov S., Karin E., Terzic J., Mucida D., Yu G. Y., Vallabhapurapu S., Scheller J., Rose-John S., Cheroutre H., Eckmann L., Karin M., IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009 15 2 103 113 2-s2.0-58649108302 10.1016/j.ccr.2009.01.001
168. Lesina M., Kurkowski M. U., Ludes K., Rose-John S., Treiber M., Klöppel G., Yoshimura A., Reindl W., Sipos B., Akira S., Schmid R. M., Algül H., Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 2011 19 4 456 469 2-s2.0-79953756112 10.1016/j.ccr.2011.03.009
169. Abe F., Dafferner A. J., Donkor M., Westphal S. N., Scholar E. M., Solheim J. C., Singh R. K., Hoke T. A., Talmadge J. E., Myeloid-derived suppressor cells in mammary tumor progression in FVB Neu transgenic mice. Cancer Immunology, Immunotherapy 2010 59 1 47 62 2-s2.0-70350111154 10.1007/s00262-009-0719-2
170. Diaz-Montero C. M., Salem M. L., Nishimura M. I., Garrett-Mayer E., Cole D. J., Montero A. J., Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunology, Immunotherapy 2009 58 1 49 59 2-s2.0-54849440346 10.1007/s00262-008-0523-4
171. Solito S., Falisi E., Diaz-Montero C. M., Doni A., Pinton L., Rosato A., Francescato S., Basso G., Zanovello P., Onicescu G., Garrett-Mayer E., Montero A. J., Bronte V., Mandruzzato S., A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood 2011 118 2254 2265 10.1182/blood-2010-12-325753
172. Raychaudhuri B., Rayman P., Ireland J., Ko J., Rini B., Borden E. C., Garcia J., Vogelbaum M. A., Finke J., Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro-Oncology 2011 13 6 591 599 2-s2.0-79960003585 10.1093/neuonc/nor042
173. Ostrand-Rosenberg S., Sinha P., Beury D. W., Clements V. K., Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. Seminars in Cancer Biology 2012 22 4 275 281 10.1016/j.semcancer.2012.01.011
174. Ochando J. C., Chen S. H., Myeloid-derived suppressor cells in transplantation and cancer. Immunologic Research 2012 54 1-3 275 285 10.1007/s12026-012-8335-1